Invest now
Glenmark Pharmaceuticals share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹2,209.75(-3.37%)October 8, 2026 15:29:46 PM IST
- NSE
- BSE
- Vol : 834.66 K (NSE + BSE)Last 20 day avg : 611.21 K
Glenmark Pharmaceuticals is trading -3.37% lower at Rs 2,209.75 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 2,283.00 & 2,180.30. Glenmark Pharmaceuticals has given 12.14% in this year & -6.52% in the last 5 days. Glenmark Pharmaceuticals has TTM P/E ratio 34.60 as compared to the sector P/E of 33.81.There are 8 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 482.92 Crores in its last quarter.Listed peers of Glenmark Pharmaceuticals include Sun Pharmaceutical Industries (-1.72%), Divi's Laboratories (-1.99%), Torrent Pharmaceuticals (-0.74%).The Mutual Fund holding in Glenmark Pharmaceuticals was at 16.76% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Glenmark Pharmaceuticals was at 20.89% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 08 Oct 2026, 07:14 PM IST
- BetaLow volatility0.83Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.06The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.22Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.20The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values36.29Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates overvaluation5.18The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Glenmark Pharmaceuticals News
Glenmark Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,752.50 | -1.72 | 4,20,473.54 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,389.00 | -1.99 | 2,49,248.45 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,675.00 | -0.74 | 1,77,815.61 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,305.00 | -1.84 | 1,05,425.52 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,115.20 | -3.36 | 1,11,241.63 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allGlenmark Pharmaceuticals Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-31 | Quarterly Results |
| 2026-05-29 | Audited Results & Final Dividend |
| 2026-01-30 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
| 2025-09-26 | Interim Dividend |
About the company Glenmark Pharmaceuticals
- IndustryBiotechnology & Drugs
- ISININE935A01035
- BSE Code532296
- NSE CodeGLENMARK
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Glenmark Pharmaceuticals Share Price FAQs
Glenmark Pharmaceuticals is trading at 2209.75 as on Thu Oct 08 2026 09:59:46. This is -3.37% lower as compared to its previous closing price of 2286.75.
The market capitalization of Glenmark Pharmaceuticals is 62364.59 Cr as on Thu Oct 08 2026 09:59:46.
The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 3 analysts have given a buy rating
- 2 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Glenmark Pharmaceuticals is 2536.85 whereas the 52 wk low is 1794.00
Glenmark Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 34.60
- Sector P/E: 33.81
- Dividend Yield: 0.22%
- D/E ratio: -
Glenmark Pharmaceuticals reported a net profit of 1361.85 Cr in 2026.
The Mutual Fund Shareholding was 16.76% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Glenmark Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.